<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>UR N-C URINARY ANTISEPTIC- hyoscyamine sulfate, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methenamine and methylene blueÂ tabletÂ </strong><br>Libertas Pharma, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>UR N-C Urinary Antiseptic</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<table width="50%">
<col align="left" valign="middle" width="75%">
<col align="right" valign="middle" width="25%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><span class="Bold">Each tablet for oral administration contains:</span></td>
<td align="right"></td>
</tr>
<tr>
<td align="left">Hyoscyamine sulfate</td>
<td align="right">0.12 mg</td>
</tr>
<tr>
<td align="left">Methenamine</td>
<td align="right">81.6 mg</td>
</tr>
<tr>
<td align="left">Methylene blue</td>
<td align="right">10.8 mg</td>
</tr>
<tr>
<td align="left">Phenyl salicylate</td>
<td align="right">36.2 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left">Sodium phosphate, monobasic</td>
<td align="right">40.8 mg</td>
</tr>
</tbody>
</table>
<p class="First"><span class="Bold"> Inactive ingredients: </span> calcium sulfate, carbopol 934P, D &amp;C #27, FD &amp;C Blue #2, FD&amp; C Red #40, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, purified water, starch 1500, talc and titanium dioxide.</p>
<p>Hyoscyamine sulfate. [620-61-1] [3(S)-endo]-Î±-(Hydroxymethyl)-benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester sulfate(2:1)(salt); 1Î±H,5Î± H-tropan-3Î±-ol(-)-tropate (ester) sulfate(2:1)(salt); 3Î±-tropanyl S-(-)-tropate; I-tropic acid ester with tropine; I-tropine tropate. C<span class="Sub">34</span>H<span class="Sub">48</span>N<span class="Sub">2</span>O<span class="Sub">10</span>S. Hyoscyamine sulfate is an alkaloid of belladonna. Exists as a white crystalline powder. Its solutions are alkaline to litmus. Affected by light, it is slightly soluble in water; freely soluble in alcohol; sparingly soluble in ether.</p>
<p><span class="Bold">Methenamine</span>. [100-97-0] 1,3,5,7- Tetraazatricyclo [3.3.1.1<span class="Sup">3</span>â€¢<span class="Sup">7</span>] decane; hexamethylenetetramine; HMT; HMTA; hexamine; 1,3,5,7- tetraazaadamantane hexamethylenemine; Uritone; Urotropin. C<span class="Sub">6</span>H<span class="Sub">12</span>N<span class="Sub">4</span>; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine (hexamethylenetetramine)exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water, soluble in alcohol and in chloroform.</p>
<p><span class="Bold">Phenyl salicylate</span>. [118-55-8] 2-Hydroxybenzoic acid phenyl ester; Salol. C<span class="Sub">13</span>H<span class="Sub">10</span>O<span class="Sub">3</span> ; mol wt 214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorus oxy-chloride on a mixture of phenol and salicylic acid. Phenyl salicylate exists as white crystals with a melting point of 41Â°-43Â° C. It is very slightly soluble in water and freely soluble in alcohol. </p>
<p><span class="Bold">Sodium phosphate, monobasic</span>. [7558-80-7] Phosphoric acid sodium salt (1:1); Sodium biphosphate; sodium dihydrogen phosphate; acid sodium phosphate; monosodium orthophosphate; primary sodium phosphate; [H<span class="Sub">2</span>NaO<span class="Sub">4</span>P:] mol wt
119.98, H 1.68%, Na 19.16%, O 53.34%, P 25.82%. Monohydrate, white, odorless slightly deliquesce crystals or granules. At 100Â°C loses all its water; when ignited it converts to metaphosphate. It is freely soluble in water and practically insoluble in alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous solution at 25Â°C: 4.5. </p>
<p><span class="Bold">Methylene blue</span>. [61-73-4] 3,7-Bis(dimethylamino) phenothiazin-5-ium chloride;
C.I. Basic Blue 9; methylthioninium chloride; tetramethylthionine chloride; 3,7-bis(dimethylamino) phenazathionium chloride. C<span class="Sub">16</span>H<span class="Sub">18</span>CIN<span class="Sub">3</span>S; mol wt 319.85, C 60.08%, H 5.67%, Cl 11.08%, N 13.14%, S 10.03%. Methylene blue (Methylthionine chloride) exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-2"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">UR N-C is indicated for the treatment of
symptoms of irritative voiding. Indicated for the relief of local symptoms, such as
<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, hypermotility, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, which accompany lower urinary tract
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Indicated for the relief of urinary tract symptoms caused by
diagnostic procedures.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosageadmin"></a><a name="section-3"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First"> FOR ORAL USE ONLY <br><span class="Bold">Adults</span>: One tablet 4 times per day by mouth, followed by liberal fluid intake. <span class="Bold">Older Children</span>: Dosage must be individualized by physician. <span class="Bold">Not recommended for use in children younger than six years.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">UR N-C is contraindicated in patients hypersensitive to
any of its ingredients. Risk benefits should be carefully considered when the
following medical problems exist: achalasia of esophagus, atony of colon,
diseases of cardiovascular system, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>;
<span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> from <span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> kinase and G6PD deficiencies, infected
<span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span>, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, toxic
<span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>; acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may be precipitated in <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span>
(such as <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="warningprecautions"></a><a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS:</h1>
<p class="First">Do not exceed recommended dosage. This
drug may make you dizzy or drowsy or cause <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; use caution while
driving, using machinery, or doing any activity that requires alertness or clear
vision. Limit alcohol consumption. Cross sensitivity and/or related problems â€“
patients intolerant of belladonna alkaloids or salicylates may be intolerant of this
medication also. Delay in gastric emptying could complicate the management of
<span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>. There have been no studies to establish the safety of prolonged
use of this product in humans. No known long-term animal studies have been
performed to evaluate carcinogenic potential.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="pregnancy"></a><a name="section-5.1"></a><p></p>
<h2>Pregnancy: Teratogenic Effects. Pregnancy Category C:</h2>
<p class="First">Hyoscyamine
sulfate and methenamine cross the placenta. Studies have not been done in
animals or humans. It is not known whether UR N-C tablets cause fetal harm
when administered to a pregnant woman or can affect reproduction capacity.
UR N-C tablets should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Infopatients"></a><a name="section-5.2"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Problems in humans have not been documented; however,
methenamine and traces of hyoscyamine sulfate are excreted in breast milk.
Accordingly, UR N-C tablets should be given to a lactating woman only if clearly
needed. Discuss the risks and benefits with your doctor.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-5.3"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Infants and young children are especially susceptible to the toxic
effect of the belladonna alkaloids (hyoscyamine sulfate). This product contains
salicylate, which is related to aspirin. Children and teenagers should not take
aspirin, aspirin-containing or aspirin-related medications if they have
<span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, or any undiagnosed illness without first consulting a
doctor. A rare but serious illness known as Reyeâ€™s syndrome may occur. This
medication is not recommended for children younger than 6 years.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="interactions"></a><a name="section-5.4"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Kidney function becomes impaired with age. This medication is
removed by the kidneys. Therefore, use with caution in elderly patients as they
may respond to usual doses of hyoscyamine sulfate with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>,
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverseeffects"></a><a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">   Cardiovascular: rapid heartbeat, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> Central Nervous System: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> Genitourinary: difficulty micturition, acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> Gastrointestinal: <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> Respiratory: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing </p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to this drug are rare. Seek immediate medical attention if you notice symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, severe <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or trouble breathing. </p>
<p>This medication can cause urine and sometimes stools to turn blue-green. This effect is harmless and will subside after medication is stopped.</p>
<p><span class="Bold">Call your doctor or physician for medical advice about side effects. The following number does not provide medical advice, but in the U.S. you may report suspected side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="drug"></a><a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS:</h1>
<p class="First">This drug should not be used with the following
medications because very serious interactions may occur: live <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> virus
vaccine, pramlintide. Because of this productâ€™s effect on gastrointestinal motility
and gastric emptying, it may decrease the absorption of other oral medications
during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause
the urine to become alkaline reducing the effectiveness of methenamine by
inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may
intensify antimuscarinic effects of hyoscyamine sulfate because of secondary
antimuscarinic activities of these medications); antacids/antidiarrheals (may
reduce absorption of hyoscyamine sulfate, concurrent use with antacids may
cause urine to become alkaline, reducing effectiveness of methenamine by
inhibiting its conversion to formaldehyde). Doses of these medications should
be spaced 1 hour apart from doses of hyoscyamine sulfate; antimyasthenics
(concurrent use with hyoscyamine sulfate may further reduce intestinal motility);
ketoconazole (patients should be advised to take this combination at least 2
hours after ketoconazole); monoamine oxidase (MAO) inhibitors (concurrent
use may intensify antimuscarinic side effects), opioid (narcotic analgesics may
result in increased risk of severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>); sulfonamides (these drugs may
precipitate with formaldehyde in the urine, increasing the danger of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>).
This is not a complete list of all drug interactions. Tell your doctor or pharmacist
of all prescription medications prior to use.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="drugabuse"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>:</h1>
<p class="First">A <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on the use of UR N-C has
not been reported nor expected based on the pharmacology of the ingredients
contained in UR N-C.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ioverdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">By exceeding the recommended dosage of UR N-C,
symptomology related to the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of its individual active ingredients may be
expected as follows:</p>
<p><span class="Bold">Hyoscyamine sulfate: </span>Symptoms associated with overdosage of UR N-C will
most probably be manifested in the symptoms related to overdosage of alkaloid
hyoscyamine sulfate. Such symptoms as dryness of mucous membranes;
dilation of pupils, hot, dry, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed skin</span>; <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>;
elevated blood pressure; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from respiratory
failure can occur due to overdosage of these alkaloids.</p>
<p><span class="Bold">Methenamine</span>: If large amounts of the drug (2-8 g daily) are used over
extended periods (3-4 weeks), bladder and <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>, painful and
frequent micturition, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span> and gross <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> may be expected.</p>
<p><span class="Bold">Phenyl salicylate</span>: Symptoms of phenyl salicylate overdosage include burning
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in throat and mouth, white necrotic lesions in the mouth, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>,
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and
<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. The symptoms, however, are not expected to be discernible from those
associated with the other active ingredients in UR N-C.</p>
<p><span class="Bold">Sodium phosphate, monobasic</span>: Symptoms of sodium biphosphate
overdosage may include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>.</p>
<p><span class="Bold">Methylene blue</span>: Symptoms of methylene blue overdosage associated with the
overdosage of UR N-C are not expected to be discernible from those associated with other active ingredients in UR N-C.</p>
<p><span class="Bold">Treatment</span>: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> or gastric lavage. Slow intravenous administration of
physostigmine in doses of 1 to 4 mg (0.5 to 1 mg in children), repeated as
needed in one to two hours to reverse severe antimuscarinic symptoms.
Administration of small doses of diazepam or baclofen to control <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Artificial respiration with oxygen if needed for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Adequate re-hydration is required. Symptomatic treatment as determined by a
doctor. </p>
<p>If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is suspected, contact your local poison center or emergency room
immediately. US residents can contact the US National Poison Hotline at 1-800-222-1222.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical"></a><a name="section-10"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First"><span class="Bold">Hyoscyamine sulfate: </span> Hyoscyamine sulfate is a parasympatholytic which
relaxes smooth muscles and thus produces an antispasmodic effect. It is well
absorbed from the gastrointestinal tract and is rapidly distributed throughout the
body tissues. Following oral administration, the drug has an onset of action of
20 to 30 minutes. The half-life is 3.5 hours. Hyoscyamine is distributed
throughout the body, crosses the blood-brain barrier, and is approximately 50%
bound to plasma proteins. It is metabolized in the liver to tropic acid, tropine,
and hyoscyamine glucuronide. Hyoscyamine is excreted primarily unchanged in
the urine within 12 hours. Its biotransformation is hepatic. </p>
<p><span class="Bold">Methenamine: </span> Methenamine, after oral administration, undergoes hydrolysis
and generates formaldehyde, which provides bactericidal or bacteriostatic
action. Methenamine is rapidly absorbed from the intestinal tract and is
excreted, for the most part, unchanged in the urine at which point it is
hydrolyzed if the urine is acidic. It is almost completely excreted (90%) in the
urine within 24 hours; of this at a pH of 5, approximately 10-30% is converted to
formaldehyde in the stomach.</p>
<p><span class="Bold">Phenyl salicylate: </span> Phenyl salicylate, a form of salicylic acid, is a mild analgesic
for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief.</p>
<p><span class="Bold">Sodium phosphate, monobasic</span>:  Sodium phosphate, monobasic increases
urinary acidity helping to maintain an acid pH necessary for the degradation of
methenamine.</p>
<p><span class="Bold">Methylene blue</span>: Methylene blue is a monoamine oxidase inhibitor with weak
antiseptic properties. It is well absorbed by the intestinal tract and rapidly
reduced to leukomethylene blue, which is stabilized in the urine. Approximately
70-80% is excreted unchanged in the urine.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="howsupplied"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">UR N-C is available as a purple tablet, imprinted â€œ293â€?:
bottles of 100 tablets, NDC 51862-175-01. Dispense in a tight, light-resistant
container as defined in the USP/NF with a child resistant closure. Store at
controlled room temperature 15Â°-30Â°C (59Â°- 86Â°F). Keep in a cool, dry place. </p>
<p><span class="Bold">WARNING: Keep this and all drugs out of reach of children.
Caution</span>: Rx Only</p>
<p><span class="Bold Italics">Manufactured for: </span><br>
Libertas Pharma, Inc. <br>
Lawrenceville, GA 30043 <br>
Iss. 04/11 175-01<br>
1000412</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Container Label</h1>
<p class="First"><span class="Bold">NDC 51862-175-01 </span></p>
<p><span class="Bold">UR N-C</span></p>
<p><span class="Bold">Urinary Antiseptic</span></p>
<p>Each tablet for oral administration contains: </p>
<p>Hyoscyamine sulfateâ€¦â€¦...12 mg </p>
<p>Methenamine.....81.6 mg </p>
<p>Methylene blue.....10.8 mg </p>
<p>Phenyl salicylate.....36.2 mg </p>
<p>Sodium phosphate monobasicâ€¦..40.8 mg </p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold">Libertas </span><br> Pharma, Inc.</p>
<div class="Figure">
<img alt="Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0a950732-ef8c-4c6b-b3d2-395c45a32ae2&amp;name=label-urnc.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UR N-C URINARY ANTISEPTICÂ 		
					</strong><br><span class="contentTableReg">hyoscyamine sulfate, methenamine, phenyl salicylate, sodium phosphate monobasic, methylene blue  tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51862-175</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.12Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</strong> (PHOSPHORIC ACID) </td>
<td class="formItem">SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</td>
<td class="formItem">40.8Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENYL SALICYLATE</strong> (PHENYL SALICYLATE) </td>
<td class="formItem">PHENYL SALICYLATE</td>
<td class="formItem">36.2Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METHENAMINE</strong> (METHENAMINE) </td>
<td class="formItem">METHENAMINE</td>
<td class="formItem">81.6Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLENE BLUE</strong> (METHYLENE BLUE) </td>
<td class="formItem">METHYLENE BLUE</td>
<td class="formItem">10.8Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 27</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">293</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51862-175-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">05/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Libertas Pharma, Inc.
							(962128943)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0a950732-ef8c-4c6b-b3d2-395c45a32ae2</div>
<div>Set id: 0a950732-ef8c-4c6b-b3d2-395c45a32ae2</div>
<div>Version: 1</div>
<div>Effective Time: 20110521</div>
</div>
</div>Â <div class="DistributorName">Libertas Pharma, Inc.</div></p>
</body></html>
